Bayer appoints Christine Roth as new Head of Oncology Strategic Business Unit at Pharmaceuticals Division
Berlin, February 3, 2022 - Bayer today announced Christine Roth as the new Head of the Oncology Strategic Business Unit at its Pharmaceuticals Division, effective March 1, 2022. She will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President Pharmaceuticals. Roth will serve on the Pharmaceuticals Executive Committee and be based in Whippany, New Jersey, USA. Prior to joining Bayer, she held the role of Senior Vice President, Global Oncology Therapy Area Head, at GlaxoSmithKline.
Christine Roth will succeed Robert LaCaze who decided to pursue other career opportunities outside of Bayer.
"Christine Roth is a highly accomplished pharma executive recognized for her exceptional track record in Oncology. Her in-depth experience and strong leadership capabilities will lift us to the next level, as we launch our late-stage Oncology pipeline and further clinically develop leading innovations to serve patients with the highest unmet medical needs," said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of the company’s Pharmaceuticals Division. "At the same time, I thank Robert LaCaze for his dedicated service in establishing our Oncology Strategic Business Unit and his outstanding leadership in bringing forward new cancer medicines to tackle unmet needs of patients."
"I feel privileged to join Bayer at a time where new exciting paths are taken to develop and bring transformative therapies to patients," said Christine Roth. "I look forward to being part of making a difference for cancer patients and their families worldwide."
Christine Roth’s prior positions include executive and senior level positions at GlaxoSmithKline, Novartis and Bristol Myers Squibb, with a focus on global product strategy and commercialization, building oncology organizations, and new product launches.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.